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Abstract
Objectives
The CHARM-01 study characterized the safety, acceptability, pharmacokinetics (PK), and
pharmacodynamics (PD) of three tenofovir (TFV) gels for rectal application. The vaginal for-
mulation (VF) gel was previously used in the CAPRISA 004 and VOICE vaginal microbicide
Phase 2B trials and the RMP-02/MTN-006 Phase 1 rectal safety study. The reduced glycer-
in VF (RGVF) gel was used in the MTN-007 Phase 1 rectal microbicide trial and is currently
being evaluated in the MTN-017 Phase 2 rectal microbicide trial. A third rectal specific for-
mulation (RF) gel was also evaluated in the CHARM-01 study.
Methods
Participants received 4 mL of the three TFV gels in a blinded, crossover design: seven daily
doses of RGVF, seven daily doses of RF, and six daily doses of placebo followed by one
dose of VF, in a randomized sequence. Safety, acceptability, compartmental PK, and ex-
plant PD were monitored throughout the trial.
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Results
All three gels were found to be safe and acceptable. RF and RGVF PK were not significantly
different. Median mucosal mononuclear cell (MMC) TFV-DP trended toward higher values
for RF compared to RGVF (1136 and 320 fmol/106 cells respectively). Use of each gel in
vivo was associated with significant inhibition of ex vivo colorectal tissue HIV infection.
There was also a significant negative correlation between the tissue levels of TFV, tissue
TFV-DP, MMC TFV-DP, rectal fluid TFV, and explant HIV-1 infection.
Conclusions
All three formulations were found to be safe and acceptable. However, the safety profile of
the VF gel was only based on exposure to one dose whereas participants received seven
doses of the RGVF and RF gels. There was a trend towards higher tissue MMC levels of
TFV-DP associated with use of the RF gel. Use of all gels was associated with significant in-
hibition of ex vivo tissue HIV infection.
Trial Registration
ClinicalTrials.gov NCT01575405
Introduction
Rectal microbicides (RM) are currently being developed to prevent, or at least significantly re-
duce, the risk of HIV acquisition associated with unprotected receptive anal intercourse
(URAI) [1]. Although evidence suggests that rates of new HIV infections in heterosexual popu-
lations are slowing, rates of new infection associated with URAI in men who have sex with
men (MSM) and transgendered women are stable or increasing [2]. The recent approval of
tenofovir disoproxil fumarate/emtricitabine for pre-exposure prophylaxis (PrEP) of HIV infec-
tion is a major step forward for HIV prevention; however, suboptimal adherence to oral PrEP
can significantly reduce PrEP efficacy [3–5].Consequently, there is an urgent need to develop
alternative approaches to PrEP, including a safe and effective RM. An RM that could be used in
a pericoital fashion by men or women, especially if it had properties that made the product
suitable for use as a sexual lubricant, might be an attractive PrEP option for individuals at risk
of HIV infection through URAI.
Attention is currently being focused on the development of tenofovir (TFV) gel as a poten-
tial RM. The vaginal formulation of TFV used in the CAPRISA 004 study [6] has been evaluat-
ed in a Phase 1 rectal safety study (RMP-02/MTN-006) [7]. Use of the gel was associated with
mild to moderate gastrointestinal symptoms including bloating, pain, urgency, and diarrhea.
The vaginal formulation (VF) of TFV is hyperosmolar (3111 mOsmol/kg) and these symptoms
may have been linked to product osmolality [8]. Consequently, the TFV gel used in a second
Phase 1 study (MTN-007) was formulated with a lower glycerin concentration (5% w/w rather
than the 20% w/w used in the RMP-02/MTN-006 vaginal formulation) to yield a product os-
molality of 836 mOsmol/kg [9]. This reduced glycerin vaginal formulation (RGVF) was better
tolerated by participants in the MTN-007 study [10] and is currently being evaluated in a
Phase 2 expanded safety study (MTN-017; ClinicalTrials.gov Identifier: NCT01687218). As
part of an ongoing program grant from the National Institutes of Health Integrated Preclini-
cal-Clinical Program (IPCP) for HIV Topical Microbicides, we have developed a third rectal-
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specific formulation (RF) TFV gel. Compared to the RGVF TFV gel, the RF TFV gel contains
less glycerin (2.5% w/w) and added carbopol (0.5% w/w), with a neutral pH and is nearly iso-
osmolar (479 mOsmol/kg); it was also safe and effective in preclinical evaluation [11].
The purpose of the Combination HIV Antiretroviral Rectal Microbicide (CHARM)-01
study was to directly compare the safety, acceptability, and pharmacokinetic (PK) and pharma-
codynamics (PD) profiles of the aforementioned TFV gel formulations in a crossover study. A
second study (CHARM-02) was designed to complement the CHARM-01 study by evaluating
systemic PK, the luminal distribution and clearance of the three gels, and their impact on mu-
cosal permeability (manuscript in progress). The design of the CHARM-01 study includes
multicompartmental PK, detailed assessment of mucosal safety (including histology, flow cy-
tometry, and rectal microflora), and a PD component that utilizes an ex vivo colorectal HIV-1
challenge assay to generate preliminary efficacy data [7,12]. The goal of the CHARM-01 study
was to provide a comprehensive data set that could guide decisions as to which TFV formula-
tion should be advanced to later stage, larger, and more expensive studies.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist are available as supporting in-
formation; see S1 CONSORT Checklist and S1 Protocol.
Ethics Statement
The study was designed by the investigators with collaborative input from CONRAD and the
NIAID/DAIDS/Prevention Sciences IPCP for HIV Topical Microbicides, as stipulated in the
award notice, and reviewed by the U.S. Food and Drug Administration (FDA). The study was
approved by the University of Pittsburgh Institutional Review Board (IRB) as well as the Uni-
versity of California at Los Angeles IRB. All subjects provided written informed consent. The
trial is registered at ClinicalTrials.gov, number # NCT01575405 and this paper is in compliance
with the CONSORT 2010 recommendations for reporting of trial results (www.consort-
statement.org) [13,14].
Study Schema
The primary objectives of the CHARM-01 study were to evaluate the clinical safety, acceptabil-
ity, and PK of three formulations of TFV 1% gel when applied rectally. The secondary study
objective was to evaluate the mucosal safety of each formulation. The study also had an explor-
atory objective to assess the preliminary efficacy of each formulation in suppressing ex vivo
HIV-1 viral replication in colorectal tissue. The CHARM-01 study was a Phase 1, double blind,
randomized crossover trial in which participants received the three TFV gel formulations (VF,
RGVF, and RF) in a randomized sequence. Each phase of product administration lasted 7 days
with a 21 (± 7) day washout period between phases of product administration (Fig 1). The first
and seventh doses of study product were administered in the clinic and the remaining five
doses were administered by the participant at home, with daily, protocol-defined telephone call
reminders to encourage product use.
During the RGVF and RF phase of dosing, participants received seven identical doses of
either the RGVF or RF TFV gel. However, during the VF phase of dosing, participants re-
ceived six doses of a hydroxyethyl cellulose (HEC) placebo gel [15], with only a final dose of
VF TFV gel. As the majority of participants in the RMP-02/MTN-006 rectal safety trial who
received VF TFV gel experienced gastrointestinal side effects (bloating, abdominal discom-
fort, and diarrhea) [7], it was considered unethical to ask participants to use more than one
dose of VF TFV gel.
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The study was conducted at two clinical sites (The University of Pittsburgh, Pittsburgh,
Pennsylvania. and the David Geffen School of Medicine, University of California at Los Ange-
les, Los Angeles, California). Enrollment began in March 2013 and the last participant com-
pleted the study in October 2013. The target sample size was 18 (nine participants at each site)
and enrolled participants were assigned at random to one of the three study formulation se-
quences. Randomization was done in blocks of three at each site to ensure balance between for-
mulation groups and the sequence of administration between sites. The randomization scheme
was stratified by site and generated by the University of Pittsburgh, Center for Research on
Health Care Data Center, using computer-generated random numbers.
The randomization assignments for up to 12 participants (24 total per site) were delivered
to the Director of Pharmacy Affairs at the Magee-Womens Research Institute (MWRI) who
held primary responsibility for maintaining the blinding and generated the product labels.
Fig 1. CHARM-01 study design.
doi:10.1371/journal.pone.0125363.g001
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Study population
The study population consisted of healthy, RAI-abstinent, HIV-uninfected, adults (male and
female) aged 18 years or older at time of screening who had been successfully vaccinated for
hepatitis B virus (HBV) or who had naturally acquired immunity to HBV, as evidenced by
HBV antibody titers. An additional inclusion criterion for female participants was the active
use of an acceptable form of contraception (e.g., barrier method, intrauterine device, hormonal
contraception, surgical sterilization, or vasectomization of the male partner). Individuals with
abnormalities of the colorectal mucosa, significant gastrointestinal symptoms (such as a history
of rectal bleeding), evidence of rectal Chlamydia trachomatis (CT) or Neisseria gonorrhea (GC)
infection, chronic HBV infection, or a requirement to use drugs that were likely to increase the
risk of bleeding following mucosal biopsy were excluded from the study.
Study products
The VF TFV gel, the RGVF TFV gel, and the Universal HEC placebo gel were manufactured
under direction from CONRAD (Arlington, VA) by DPT Laboratories (San Antonio, TX).
DPT Laboratories also manufactured the RF TFV gel under direction of Dr. Lisa Rohan’s
Group at MWRI. HTI applicators (HTI Plastics, Lincoln, NE) were used to deliver gel in the
CHARM-01 study. These applicators had been initially designed for vaginal use and have been
used in all of the previous vaginal microbicide trials with TFV gel. They have also been used
rectally in the RMP-02/MTN-006 and MTN-007 studies [7,10]. Each opaque pre-filled applica-
tor was packaged with a plunger and labeled with a code to preserve the identity of the formula-
tion. Each pre-filled applicator contained a dose of approximately 4 mL of TFV gel or the HEC
placebo. The pre-filled applicators were shipped directly to study site pharmacies and were
stored by and dispensed from the site pharmacy.
Each participant was assigned applicators based on the randomization number. At Visits 3,
6, and 9 the participant’s first dose of study product was administered by the clinical staff. Dur-
ing the period of daily administration, study participants were instructed to insert one dose of
gel into the rectum once daily for five days. A final dose of study product was administered by
clinic staff at Visits 4, 7, and 10.
Study procedures
There were a total of eleven study visits and one follow-up phone call. After obtaining informed
consent all participants were screened with a thorough medical history, a targeted physical ex-
amination, a digital rectal examination, and rectal swabs for CT/GC nucleic acid amplification
testing (NAAT). Urine was also collected for CT/GC NAAT and for pregnancy testing in the
female participants (pregnancy testing was repeated at all subsequent clinical visits). Blood was
collected for safety labs (complete blood count, urea nitrogen, creatinine, alanine aminotrans-
ferase, and aspartate aminotransferase) and serology (syphilis, HIV-1, hepatitis B, and herpes
simplex 1 and 2). Participants who met the aforementioned inclusion criteria during the
Screening Visit were enrolled into the study. The Enrollment Visit occurred within 28 days of
screening. At the Enrollment Visit, participants were randomized, a web-based behavioral
questionnaire was administered, and a rectal examination and focused physical examination
were performed. Rectal swabs were collected for CT/GC. Rectal sponges for quantification of
cytokines/chemokines in rectal secretions, and PK were also collected. Participants then re-
ceived a normal saline pH 7.4 enema. A flexible sigmoidoscope was inserted into the rectum
and 21 biopsies were collected at approximately 15 cm from the anal verge. Biopsies were used
for histology, gene expression, flow cytometry, PK, and ex-vivo tissue challenges. At Visits 3, 6,
and 9 (Treatment Initiation Visits), all participants had a single applicator of study gel inserted
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into the rectum. Prior to product insertion, samples were collected for CT/GC, microflora and
cytokines. At Visits 4, 7, and 10 (Last Dose Treatment Visits) sponges were collected for quan-
tification of cytokines in rectal fluid. A normal saline enema was then administered followed
by a single dose of study product. Approximately 30 minutes later (± 15 minutes) blood, and in
females, self-collected vaginal sponges were collected for PK studies. A sigmoidoscope was
then inserted and the same rectal tissue biopsy samples were collected as described during the
Enrollment Visit. Additional blood and rectal/vaginal sponges were collected at 2 hours (± 30
minutes) and 4 hours (± 30 minutes) after product insertion. At Visits 5, 8, and 11 (conducted
18–30 hours after Visits 4, 7, or 10) blood and rectal/vaginal sponges were collected for PK.
Rectal swabs were collected for assessment of microflora after gel use. A web-based question-
naire was also conducted at the end of each period of gel use. At Visit 11 only, blood was col-
lected for HBsAg serology. A brief qualitative interview was conducted after Visit 11 to assess
overall product acceptability. A final telephone call follow-up assessment was conducted within
14 days of Visit 11.
Clinical safety and laboratory assessments
Emergent adverse events (AEs) were graded using the Division of AIDS Table for Grading the
Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004 as well as Adden-
dum 1 and 3 (Female Genital and Rectal Grading Table for Use in Microbicide Studies (http://
rsc.tech-res.com/safetyandpharmacovigilance/). In cases where an AE was covered in both ta-
bles, the Female Genital or Rectal Grading Table for Use in Microbicide Studies was the grading
scale utilized.
Product acceptability and adherence
Overall product like (or dislike) and likelihood of gel use in the future were assessed using an
internet-based computer-assisted self-interview (CASI). The Wisebag, a lunch bag-style con-
tainer with an electronic events-monitoring system, is designed as a real-time indirect objective
measure of microbicide gel use and was used in the CHARM-01 study to monitor product ad-
herence [16].
Mucosal safety
Histology. A qualitative scoring system developed for inflammatory bowel disease (IBD)
research [17] and adapted for use in RM trials [18] was used to characterize potential product-
associated injury with a scale of 1 (normal) to 5 (mucosal erosion or ulceration).
Rectal microflora. Rectal microflora was characterized using previously described semi-
quantitative culture analysis techniques [19,20] that have been used in other RM Phase 1 stud-
ies [7,10].
Mucosal T cell phenotype. Mucosal mononuclear cells (MMC) were isolated from rectal
biopsies using a combination of mechanical and enzyme digestion as previously described [10].
Flow cytometric analysis was performed on a BD LSRFortessa cytometer (BD Biosciences, San
Jose, CA). All data were stored in list mode and analyzed with BD FACSDIVA operating sys-
tem and Flow Jo (Tree Star, Inc., Ashland, OR). All antibodies were purchased from BD Biosci-
ences, San Jose, CA (PerCP-CD45, Clone 2D1; Pacific Blue-CD3, Clone UCHT1;
PE-Cy7-CD4, Clone SK3; APC-H7-CD8, Clone SK1; FITC-CD69, Clone FN50; APC-CD184
(CXCR4), Clone 12G5 and PE-CD195 (CCR5)) and titrated under assay conditions to deter-
mine an optimum saturating dilution. Cells were stained with LIVE/DEAD Fixable Aqua stain
fluorescence (Life Technologies, Eugene, OR) to define viable cells. The gating strategy used in
this study can be found in S1 Fig.
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Pharmacokinetic procedures
Blood plasma, peripheral blood mononuclear cells (PBMCs), vaginal and rectal fluid, and rectal
tissue were obtained before rectal dosing (Visit 2) and 30 minutes after the seventh dose of the
gels (Visits 4, 7, and 10). At 2, 4, and 24h after the final dose, blood plasma, PBMCs, and rectal/
vaginal fluid samples were obtained (Visits 5, 8, and 11).
Sample Processing. TFV and TFV-DP concentrations were determined via validated liq-
uid chromatographic-tandem mass spectrometric (LC-MS/MS) methods at The Johns Hop-
kins University Clinical Pharmacology Analytical Laboratory as described previously [21]. All
assays were validated following the recommendations of the FDA, Guidance for Industry: Bioa-
nalytical Method Validation guidance document. TFV concentrations were determined in plas-
ma, rectal fluid, and vaginal fluid. TFV-DP concentrations were determined for PBMCs, rectal
tissue homogenates, and rectal MMCs. The measured value from each PK assay was used un-
less the PK value was determined to be between the lower limit of quantification (LLOQ) and
the lower limit of detection (LLOD), in which case, a number equal to half that assay’s LLOQ
was imputed for that PK value.
Ex vivo tissue biopsy challenge assay
At Enrollment (Visit 2) and post-product exposure timepoints (Visits 4, 7, and 10), endoscopic
biopsies were collected in 20 mL RPMI (with 1.125 μg/mL of Fungizone and 0.5 mg/mL of
Zosyn) and transported to the laboratory for ex vivo infection within 1–2 hours using a com-
mon viral stock of HIV-1BaL (10
4 TCID50), as previously described [7,12]. Supernatants for p24
quantification were collected every three days during each 14-day infectibility assay (Days 4, 7,
11 & 14). Results were adjusted for biopsy weight, averaged across quadruplicate assays, and re-
ported as Day 14 cumulative p24 (p24 HIV antigen ELISA; NCI, Bethesda, MD) where the as-
say’s LLOQ was 10 pg/mL. Non-detectable cumulative p24 measures at Day 14 were converted
to 1/2 the LLOQ prior to log transformation.
Analysis of outcomes
Below, we describe the analyses used for each of the primary and secondary outcomes. SAS ver-
sion 9.2 was used for the statistical analyses. The primary outcome of safety was assessed at the
5% type I error rate. The target sample size of 18 was chosen to ensure an 85% probability of
observing at least one Grade 2 or higher adverse event in an arm when the true event rate is
10%. Each of the secondary outcomes was assessed at the nominal significance level without
adjustments for multiplicity.
Safety. For safety analysis, the number and frequency of Grade 2 adverse events (AEs)
were tabulated for each of the three study formulations. To determine the extent of AEs, the
proportion of subjects that experienced an AE was calculated for each study formulation. The
rate of safety events was compared between the RF formulation and either the VF or RGVF for-
mulations using McNemar’s test for each comparison. This was conducted after the final dos-
ing visits (Visits 4, 7, and 10, respectively).
Acceptability. We calculated the proportion of participants who reported product charac-
teristics that were considered to be a barrier in use, operationalized as having a rating of lower
than 3 on a 5-point Likert scale, in disliking or likelihood of future barrier in use. Acceptability
was defined as the converse (rating of 3). This was calculated for each of the following prod-
uct characteristics: “consistency”, “color”, “smell”, “taste”, “stickiness”, “feeling inside rectum”,
“need for lubrication”, and “sexiness”. McNemar’s test was then used to compare each pair of
formulations with respect to acceptability.
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Pharmacokinetics. TFV-based gel formulations’ PK were evaluated in six compartments
(plasma, PBMCs, rectal fluid, rectal tissue, rectal MMCs, and cervicovaginal fluid) after rectal
administration of the study product. For matrices other than tissue which were sampled mul-
tiple times after the last dose, the 24 hour post-dose concentration and time profiles were ex-
amined following the final rectal dose of each TFV-containing study product. This occurred
after 7 doses for the RF and RGVF gels and after 1 dose for the VF gel). TFV (or TFV-DP in
PBMCs) were characterized in terms of maximum concentration (Cmax), time to maximum
concentration (Tmax), and area under the TFV concentration-time curve from 0 to 24h
(AUC0-24 [log-linear trapezoidal method]) using non-compartmental methods (WinNonlin
v. 6.3 software, Pharsight, St. Louis, MO). Rectal biopsies, which were sampled only once with
each product, were taken 30 minutes after each final study product dose to determine TFV
and TFV-DP concentrations in tissue homogenates and TFV-DP in MMCs. We performed
paired comparisons between RF and RGVF using the Wilcoxon rank sum test with exact two-
sided significance test (alpha  0.05). VF PK was not compared to either RF or RGVF due to
non-steady state conditions; only one TFV-containing dose was given during the VF phase of
the study.
Mucosal Immunotoxicity. The association of mucosal parameters with study products
was examined. Flow cytometry and histopathology parameters were collected at the enroll-
ment/baseline visit (Visit 2) as well as after the 7th dose of each formulation (Visits 4, 7, and
10). Changes between each of the latter visits and the baseline visit were calculated for the flow
cytometry parameters and used as the outcome for the analysis. Microflora anaerobic and fac-
ultative parameters were collected at the 1st dose (Visits 3, 6, and 9) and 24hr post dose for
each formulation (Visits 5, 8, and 11), and changes between each 1st and 24hr post dose (i.e.
Visit 5 minus Visit 3, Visit 8 minus Visit 6 etc.) were calculated and used as the outcome. GEE
models were utilized for all outcomes with different link functions to account for the distribu-
tional nature (i.e. continuous versus binary). In addition, we assumed an exchangeable within-
subject correlation, which assumes the correlation between any two visits is the same. Predic-
tors in the model included drug formulation, visit (or stage), and their interaction. We first
tested the interaction to confirm the non-existence of a drug formulation carryover effect. If
significant, we based our inference on information at Stage 1. Otherwise, we ran an additive
model (w/o interaction term) as our final model. Each participant served as his or her own con-
trol and effects were tested using two-sided Wald significance tests with α = 0.05.
Pharmacodynamics. Cumulative p24 at Day 14 was used as the primary measure for ex
vivo tissue infectibility. This was measured at the enrollment/baseline visit (Visit 2) as well as
30 minutes after the 7th dose of each formulation (Visits 4, 7, and 10). Changes between each of
the latter visits and the baseline visit were calculated for 14-day cumulative p24. A natural log
transformation was then taken and used as the outcome for the analysis. GEE models were uti-
lized with an identity link function and an exchangeable correlation structure to account for
the within-participant correlation. Predictors in the model included drug formulation, visit (or
stage), and their interaction. Due to the crossover design of the trial, we first tested the interac-
tion to confirm the non-existence of a drug formulation carryover effect. If significant, we
based our inference on information at Stage 1. Otherwise, we ran an additive model (w/o inter-
action term) as our final model.
Correlation between Pharmacokinetic and Pharmacodynamic data. TFV measurements
from three compartments (rectal fluid, plasma, and rectal tissue) and TFV-DP measurements
from three compartments (PBMC, MMCs, and rectal tissue) were log10 transformed and
paired with the corresponding log10 transformed cumulative p24 at Day 14 from the ex vivo tis-
sue HIV infections for each subject and sampling time. A linear regression model was fitted to
the paired PK:PD data set for each PK compartment, where subject was a covariate [22].
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Results
Enrollment and retention
A total of 14 participants (11 men and 3 women) were enrolled and randomized in the study
(Fig 2), 12 of whom completed the study. The majority of participants were white (57%) with a
mean age of 37.7 (± 14.3) years (Table 1). There was no statistical difference between sites in
gender composition or the proportion of white participants, although there was a difference
with respect to age (41.7 versus 23.0; P = 0.04) with UCLA having an older cohort. One female
participant was enrolled but developed pyelonephritis prior to product exposure and was re-
moved from the study. A second participant was randomized to receive the RGVF gel as the
first study product. The participant completed Visit 5 but was subsequently withdrawn due to
gastrointestinal symptoms including bloating and abdominal discomfort suggestive of irritable
bowel syndrome. All other participants completed the study. Averaged across all study visits,
the proportion of completed administrative procedures, clinical procedures, clinical laboratory
sample collection, and research laboratory sample collection was 89%, 87%, 96%, and
86% respectively.
Safety
Adverse events were generally mild (Grade 1, N = 25, 86% of all AEs) or moderate (Grade 2,
N = 2, 7% of all AEs). Two Grade 3 events occurred during the VF TFV phase of the study.
Fig 2. Flow diagram of participant progress through the CHARM-01 study.
doi:10.1371/journal.pone.0125363.g002
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Both Grade 3 events were in a female participant with pyelonephritis which occurred prior to
product administration and were considered unrelated to study product. Gastrointestinal ad-
verse events were common but the majority 17/18 (94%) were mild (Table 2). There were no
significant differences in the proportion of participants with Grade 2 or higher adverse
events across the phases of the study (Table 2).
Acceptability
Acceptability was evaluated for the following product characteristics; perception of product
consistency, smell, taste, color, stickiness, lubrication, feeling inside the rectum, and sexiness.
The ranges for product acceptability characteristics were 75%-100% (RF gel), 82%-100%
Table 1. Baseline demographic data by site.
Variables UCLA(n = 11) PITT(n = 3) Overall(n = 14)
Age 41.7 ± 13.6 23.0 ± 1.7 37.7 ± 14.3
Male 9(81.82%) 2(66.67%) 11(78.57%)
Race
White 6(54.55%) 2(66.67%) 8(57.14%)
Black or African American 4(36.36%) 1(33.33%) 5(35.71%)
American Indian or Alaska Native 1(9.09%) 0(0.00%) 1(7.14%)
Hispanic
No, not of Hispanic, Latino/a, or Spanish origin 9(81.82%) 3(100.00%) 12(85.71%)
Yes, Mexican, Mexican American, Chicano/a 1(9.09%) 0(0.00%) 1(7.14%)
Yes, Another Hispanic, Latino/a or Spanish origin 1(9.09%) 0(0.00%) 1(7.14%)
doi:10.1371/journal.pone.0125363.t001
Table 2. Adverse events by formulation.
Overall Events Severity Overall RF TFV RGVF TFV VF TFV
N % N % N % N %
Grade 1 25 86.21 7 100.00 7 87.50 11 78.57
Grade 2 2 6.90 0 0.00 1 12.50 1 7.14
Grade 3 2 6.90 0 0.00 0 0.00 2 14.29
Total 29 100 7 100 8 100 14 100
Overall Events By System
Gastrointestinal Grade 1—Mild 17 94.44 5 100 5 83.33 7 100
Gastrointestinal Grade 2—Moderate 1 5.56 0 0.00 1 16.67 0 0.00
Total 18 100 5 100 6 100 7 100
Genitourinary Grade 2—Moderate 1 33.33 0 0.00 0 0.00 1 33.33
Genitourinary Grade 3—Severe 2 66.67 0 0.00 0 0.00 2 66.67
Total 3 100 0 0.00 0 0.00 3 100
HEENT Grade 1—Mild 2 100 0 0.00 2 100 0 0.00
Total 2 100 0 0.00 2 0.00 0 0.00
Neurological Grade 1—Mild 5 100 2 100 0 0.00 3 100
Total 5 100 2 100 0 0.00 3 100
Respiratory Grade 1—Mild 1 100 0 0.00 0 0.00 1 100
Total 1 100 0 0.00 0 0.00 1 100
Proportion of participants with Grade 2 adverse events 0 0.00 1 7.69 1 7.69
doi:10.1371/journal.pone.0125363.t002
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(RGVF gel), and 82%-100% (VF). There were no significant differences in acceptability for any
of the characteristics evaluated across the three study products.
Adherence
Wisebags were used as a surrogate for product adherence for the five doses that were to be ad-
ministered at home. Participants at both sites indicated on self-report that they administered
the five consecutive doses of gel for each of the three formulations. This was also reported by
count of used and unused applicators. Unfortunately, due to a number of equipment and data
retrieval problems the self-report adherence data could not be supported or refuted by Wisebag
data (manuscript in preparation).
Mucosal safety
Histology. There were no significant increases in histology scores between Visit 2 (Enroll-
ment) and Day 7 of dosing (Visits 4, 7, or 10), or across the three study formulations (data not
shown).
Mucosal T cell phenotype. Significant changes in T cell phenotype between Visit 2 and
Visits 4, 7, or 10 across the three study formulations are summarized in Table 3 (complete data
are provided in S1 Table). Briefly, a significant increase between Visit 2 and Day 7 of dosing
was seen for CD3+/CD45+ T cells (RF TFV gel (P = 0.038) and VF TFV gel(P = 0.0005)).
A significant decrease between the time of enrollment and Day 7 of dosing was seen for the
following T cell phenotypes: CXCR4+/CD4+ (VF TFV gel; P = 0.048), CD69+/CD4+ (VF TFV
gel; P = 0.0188), CXCR4+/CCR5+/CD4+ (VF TFV gel; P = 0.0157), CXCR4+/CD8+ (VF TFV
Table 3. Flow cytometry data.*
Flow parameter Enrollment(n = 14) Mean at 7th Dose Change at 7th Dose(n = 13) P value**
Mean (SD), Median (25%, 75%) N, Mean (SD), Median (25%, 75%) Mean (SE)
% CD3+ from CD45+ 44.4 (17.4), 47.2 (34.6, 58.9)
Enrollment vs. RF D7 11, 53.8 (16.4), 54.8 (46.9, 66.2) 12.23 (5.89) 0.0380
Enrollment vs. HEC/VF D7 12, 54.6 (18.9), 58.3 (49.8, 63.4) 11.98 (3.46) 0.0005
% CXCR4+ from CD4+ 71.5 (16.1), 70.3 (57.9, 84.5)
Enrollment vs. HEC/VF D7 12, 61.1 (23.2), 61.4 (55.0, 79.5) -10.68 (5.40) 0.0480
Change at 7th Dose (RGVF v HEC/VF) 16.4 (6.70) 0.0142
% CD69+ from CD4+ 83.4 (6.0), 83.9 (80.4, 87.4)
Enrollment vs. HEC/VF D7 12, 80.5 (4.9), 82.3 (78.7, 83.5) -2.27 (0.97) 0.0188
% CXCR4+ and CCR5+ from CD4+ 55.6 (11.9), 55.1 (43.8, 66.2)
Enrollment vs. HEC/VF D7 12, 45.4 (15.9), 48.7 (41.2, 53.9) -10.16 (4.20) 0.0157
Change at 7th Dose (RGVF v HEC/VF) 15.70 (5.58) 0.0049
% CXCR4+ from CD8+ 51.2 (17.1), 47.8 (40.2, 68.1)
Enrollment vs. HEC/VF D7 12, 39.3 (18.8), 38.3 (33.9, 54.2) -13.38 (4.58) 0.0035
% CD69+ from CD8+ 85.7 (6.1), 84.7 (82.1, 90.5)
Enrollment vs. RGVF D7 13, 71.4 (26.6), 80.2 (78.1, 84.3) -13.54 (6.17) 0.0283
Change at 7th Dose (RF v RGVF) 12.80 (6.02) 0.0336
% CXCR4+ and CCR5+ from CD8+ 43.2 (13.1), 42.5 (35.6, 48.0)
Enrollment vs. HEC/VF D7 12, 31.5 (13.8), 34.0 (29.1, 37.7) -12.51 (3.66) 0.0006
*Table 3 only lists phenotypes where signiﬁcant variation was noted between visits of between products. Complete ﬂow cytometry data are provided in S1
Table
**P-value from signiﬁcance test of relevant contrast from GEE model.
doi:10.1371/journal.pone.0125363.t003
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gel; P = 0.0035), CD69+/CD8+ (RGVF TFV gel; P = 0.0283), and CXCR4+/CCR5+/CD8+ (VF
TFV gel; P = 0.0006). Significant differences were seen between formulations for the following
T cell phenotypes: CXCR4+/CD4+ (RGVF TFV gel versus VF TFV gel; P = 0.0142), CXCR4
+/CCR5+/CD4+ (RGVF TFV gel versus VF TFV gel; P = 0.0049), and CD69+/CD8+ (RF TFV
gel versus RGVF TFV gel; P = 0.0336).
Rectal microflora. Bacteroides fragilis was increased in the 24 hr Post Dose sample com-
pared to the 1st Dose sample (RGVF gel; P = 0.046) and reduced in the 24 hr Post Dose sample
compared to the 1st Dose sample (VF gel; P = 0.018). Lactobacillus (H2O2 negative) was re-
duced in the 24 hr Post Dose sample compared to the 1st Dose sample (RF gel; P = 0.0325).
Gram positive rods were reduced in the 24 hr Post Dose sample compared to the 1st Dose sam-
ple (RF gel; P = 0.0422). Viridans streptococcus was reduced in the 24 hr Post Dose sample
compared to the 1st Dose sample (RF gel; P = 0.0110).The majority of changes resulted in a de-
crease in the prevalence of these organisms (Table 4; complete data are provided in S2 Table).
Pharmacokinetics
TFV moieties were detected in all compartments sampled, except for PBMC TFV-DP which
was below the LLOQ for all products (Table 5). The plasma TFV concentration-time profile
(S2 Fig), Cmax, Tmax, and AUC0-24 were not significantly different for the RF and RGVF prod-
ucts. There were no differences between RF and RGVF in TFV or TFV-DP in rectal tissue ho-
mogenate. Median mucosal mononuclear cell (MMC) TFV-DP trended toward higher values
for RF compared to RGVF (1136 (IQR; 473–2200) and 320 (IQR; 170–1151) fmol/106 cells re-
spectively). As mentioned previously, only a single exposure (Day 7) of the vaginally-formulat-
ed TFV 1% gel was given to those during their randomization to the VF arm; consequently, the
VF product findings for PK are not summarized here.
Table 4. Microbiology data.
1st Dose 24hr Post Dose Change(n = 13) P Value**
Descriptive Statistics* Descriptive Statistics
N, Mean (SD), Median
(25%, 75%)
N, Mean (SD), Median
(25%, 75%)
Diff (SE)
Rectal Microﬂora Cultures (Anaerobic)
Bacteriodes fragilis
RGVF: 1st Dose vs. 24hr Post Dose 13, 2.2 (1.6), 2 (1, 4) 13, 3.2 (1.1), 3 (3, 4) 1.05 (0.53) 0.0460
HEC/VF: 1st Dose vs. 24hr Post Dose 12, 3.1 (0.7), 3 (3, 3.5) 12, 2.1 (1.2), 2 (2, 3) -0.99 (0.32) 0.0018
Change at 24hr Post Dose (RGVF v HEC/VF) 2.04 (0.73) 0.0051
Rectal Microﬂora Cultures (Facultative Isolates)
Lactobacillus, H2O2 negative
RF: 1st Dose vs. 24hr Post Dose 12, 0.8 (1.1), 0 (0, 2) 12, 0.3 (0.6), 0 (0, 0) -0.57 (0.26) 0.0325
Change at 24hr Post Dose (RF v HEC/VF) -0.74 (0.24) 0.0023
Gram positive rods, other
RF: 1st Dose vs. 24hr Post Dose 12, 2.0 (1.1), 2 (1, 3) 12, 1.4 (1.3), 2 (0, 2.5) -0.68 (0.34) 0.0422
Viridans streptococcus, H2O2-positive
HEC/VF: 1st Dose vs. 24hr Post Dose 12, 1.3 (1.4), 1.5 (0, 2) 12, 0.8 (1.2), 0 (0, 1.5) -0.50 (0.20) 0.0110
Escherichia coli
Change at 24hr Post Dose (RF v HEC/VF) -0.98 (0.39) 0.0117
*Semi-quantitative score (0 = no growth; 4 = 107 colony forming units/mL)
** P-value from signiﬁcance test of relevant contrast from GEE model.
doi:10.1371/journal.pone.0125363.t004
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Pharmacodynamics
Exposure to all three formulations resulted in a significant reduction in ex vivoHIV infection
in rectal tissues collected 30 minutes after the last dose of each study product (Visits 4, 7, and
10) as compared to baseline (Visit 2) (Table 6). In addition, the degree of viral suppression as-
sociated with one week of daily dosing of the RF TFV gel was significantly greater than that ob-
served 30 minutes after the single (Day 7) dose of the VF TFV gel. There was no difference
between the RF and RGVF TFV gels in terms of the degree of viral suppression seen in the
explant tissue.
Correlation between pharmacokinetics and pharmacodynamics
There was a significant negative correlation between tissue concentrations of TFV (P< 0.05; Fig
3), tissue TFV-DP, MMC TFV-DP, rectal fluid TFV, and tissue HIV-1 infection (S3 Fig). This
observation was observed and consistent for all three formulations. Significant negative correla-
tions between tissue HIV infection and plasma TFV concentrations for the RF and VF TFV gels
Table 5. Pharmacokinetic data are summarized as median (interquartile range).*
Matrix Moiety PK Units RF TFV RGVF TFV VF TFV
Plasma TFV Cmax ng/mL 7.1 (3.5–11.9) 6.0 (4.3–7.1) 5.1 (3.3–6.2)
AUC ng*hr/mL 78 (33–135) 64 (28–97) 36 (23–57)
PBMC TFV-DP fmol/M All BLQ All BLQ All BLQ
Colon tissue TFV 30’ ng/mg 2.9 (0.5–5.8) 1.4 (0.7–3.7) 1.0 (0.1–9.2)
TFV-DP 30’ ng/mg 10.3 (BLQ-36.8) 5.2 (BLQ-12.8) BLQ (BLQ-6.4)
Colon tissue MMC TFV-DP 30’ fmol/M 1136 (473–2200) 320 (170–1151) 91 (19–367)
Rectal Fluid TFV Cmax ng/mL 8.1x10
5 (1.8 x105-1.6 x106) 9.4 x105 (4.3x105-1.4x106) 3.6x105 (8x104-8.2x105)
AUC ng*hr/mL 1.4 x106 (4.5x105-2.9x106) 1.4 x106 (6.6x105-2.5x106) 7.9x105 (5x105-1.4x106)
Vaginal Fluid** TFV Cmax ng/mL 186; 7,526 1,824; 2,460 39; 132
AUC ng*hr/mL 263; 4,469 1,381; 2,556 22; 118
BLQ; Below the level of quantiﬁcation
doi:10.1371/journal.pone.0125363.t005
Table 6. Tissue pharmacodynamic data.
Tissue Infection and 14-day Log10 Cumulative
p24 pg/mL
Enrollment(n = 11) Mean at 7th Dose Change at 7th Dose
(n = 11)
P
value*
Mean (SD), Median (25%,
75%)
N, Mean (SD), Median (25%,
75%)
Mean (SE)
2.93 (0.38), 3.01 (2.71,
3.08)
Enrollment vs. RF D7 10, 1.87 (1.03), 1.99 (0.73,
2.92)
-1.02 (0.26) <0.0001
Enrollment vs. RGVF D7 11, 2.15 (1.01), 2.58 (0.89,
2.78)
-0.82 (0.24) 0.0008
Enrollment vs. HEC/VF D7 11, 2.41 (0.51), 2.43 (2.20,
2.87)
-0.51 (0.17) 0.0024
Change at 7th Dose (RF v RGVF) -0.21 (0.23) 0.3610
Change at 7th Dose (RF v HEC/VF) -0.51 (0.25) 0.0420
Change at 7th Dose (RGVF v HEC/VF) -0.31 (0.21) 0.1388
* P-value from signiﬁcance test of relevant contrast from GEE model.
doi:10.1371/journal.pone.0125363.t006
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were observed (P< 0.01); however, this trend was not repeated for the RGVF (P> 0.05) TFV
gel. When all data were pooled, there was an overall significant correlation between plasma TFV
concentrations and inhibition of colorectal tissue HIV-1 infection (P< 0.05).
Discussion
With the important caveat that only one dose of the VF TFV gel was administered in this
study, the CHARM-01 study demonstrated that all three formulations of TFV gel evaluated in
this Phase 1 study were safe and acceptable. Rectal exposure to study products was associated
with the detection of TFV in plasma, rectal fluid, and rectal tissue and TFV-DP in rectal tissue
and tissue MMC but not in PBMCs. As previously reported, rectal exposure to TFV gels was
also associated with detection of TFV in vaginal fluids [7, 23]. Use of all three formulations re-
sulted in significant suppression of HIV-1 viral replication in the ex vivo colorectal challenge
assay, which correlated with local tissue concentrations of TFV.
We were unable to fully enroll the CHARM-01 study due to a combination of slow partici-
pant accrual and product expiration. In the early stage of product development microbicide gel
formulations may have limited stability. It is therefore critical that the timing of studies take
into consideration product expiration. However, as with our study, unanticipated regulatory
delays or slow enrollment may still lead to premature closure of a study.
Fig 3. PK/PD relationship between rectal tissue TFV and colorectal tissue supernatant HIV-1 p24 after
use of the VF TFV gel, the RGVF TFV gel, and the RF TFV gel. The black line represents PK/PD
relationship for the entire data set across all three formulations.
doi:10.1371/journal.pone.0125363.g003
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The majority of reported adverse events in the study were gastrointestinal and of mild sever-
ity. There were no differences in rates of adverse events across the three formulations although
as mentioned above the VF TFV gel exposure was limited to one exposure which is probably
why we did not see more gastrointestinal events in the VF TFV gel phase of dosing. The RGVF
was evaluated and found to be safe and acceptable in the MTN-007 rectal safety study [10] and
had a similar profile in the CHARM-01 study. Despite the osmolality of the RF gel being half of
the RGVF TFV gel (479 versus 846 mOsmol/kg, respectively), there was no difference in their
respective safety profiles.
All three formulations were acceptable to the study participants. Of note, the VF TFV gel
phase of dosing in CHARM-01 only included exposure to one dose of the VF TFV gel preceded
by six daily doses of a HEC placebo gel. This likely explains why exposure to the VF TFV gel
was more acceptable than the seven doses of VF TFV gel participants received in the RMP-02/
MTN-006 study [7]. In the context of the CHARM-01 protocol, acceptability was based upon
the assessment of a series of product characteristics that might be considered as potential barri-
ers to use of these products such as taste, odor, and smell. In previous rectal and vaginal micro-
bicide studies, including the RMP-02/MTN-006 study, acceptability has been assessed only on
the basis of intentionality for future use of the product [24].
As with previous RM studies, the CHARM-01 study explored the potential impact of prod-
uct administration on mucosal safety as assessed by histology, flow cytometry of gastrointesti-
nal derived T cells, and rectal microflora. There were no histological changes noted in the
study. There was a significant increase in CD3+/CD45+ T lymphocytes associated with 7 day
exposure to the RF TFV gel. However, there were no significant increases in HIV-1 target cells
defined by CD4+, CCR5+, or CXCR4+ phenotypes nor were there any significant changes in
activation phenotype defined by CD69+, CD38+, or HLA-DR+ phenotypes. In the absence of
such changes, it is unclear whether the increase in CD3+/CD45+ T lymphocytes associated
with exposure to the RF gel might still be associated with a quantitative increase in HIV-1 tar-
get cells such as CD4+/CCR5+ T cells. Another limitation of this study is that we only charac-
terized T cell phenotypes and in future it would be worthwhile broadening the flow panel to
include other cells of myeloid lineage such as monocytes and macrophages that might play an
important role in the mucosal response to HIV infection and that might be impacted by expo-
sure to microbicide candidates. Flow cytometric analysis of gut-associated lymphoid tissue
(GALT) T cell populations may be more useful in evaluating products like the CCR5 antagonist
maraviroc that have been associated with changes in activation phenotype and CCR5 expres-
sion in GALT [25]. Such studies are currently ongoing in the HPTN-069 study of oral PrEP
(ClinicalTrials.gov Identifier: NCT01505114) and will be used in the CHARM-03 study which
will evaluate rectal and oral maraviroc products. Modest, but significant changes in rectal mi-
croflora were noted for five of the 24 organisms evaluated using semi-quantitative culture tech-
niques. It is uncertain whether these changes could be associated with exposure to the TFV
gels. However, it is known that zidovudine has antibacterial activity [26]. The clinical signifi-
cance of these changes is uncertain and may be better understood after longer term studies
and/or the use of newer technologies to characterize and quantify the rectal microbiome in mi-
crobicide trials [27]. An alternative approach to the assessment of mucosal safety is to incorpo-
rate systems biology to characterize the mucosal transcriptome and proteome before and after
microbicide exposure. Using this approach, we have previously documented significant
changes in rectal mucosal biology associated with TFV exposure including significant changes
in mitochondrial function [10]. Similar evaluations are ongoing with samples from CHARM-
01 participants and will be reported separately.
The compartmental PK data from CHARM-01 are similar to PK data generated in the RMP-
02/MTN-006 study [7, 28]): rectal exposure to TFV gels is associated with minimal systemic
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exposure, lack of drug detection in PBMCs, high concentrations in rectal tissue/fluid, and detec-
tion in vaginal fluid. MMC TFV-DP trended toward ~2-fold greater concentrations following RF
when compared to RGVF. Otherwise, there were no PK differences between these two products.
Single dose VF PK values cannot be fairly compared to the drug accumulation in steady-
state RF and RGVF PK values after 7 doses. For example, based on our single dose VF PK data
and the long TFV and TFV-DP half-life within most of the matrices tested [29], accumulation
of TFV and TFV-DP after 7 daily VF doses would match or exceed the concentrations seen
with the RF and RGVF products in this study.
The ex vivoHIV-1 tissue biopsy challenge assay has become an important component in
the evaluation of candidate microbicides [30] and has been used to generate preliminary effica-
cy data in several RM studies [28, 31]. In the CHARM-01 study, all three formulations were as-
sociated with ex vivo viral suppression in colorectal tissue are these data are in keeping with
previous Phase 1 RM studies where the use of both VF TFV gel and UC781 was associated with
significant inhibition of explant infection [7,12]. These findings are impressive, especially for
the VF as only one dose of active product was delivered in vivo with tissues acquired within
15–45 minutes following product insertion and it is known that the HEC gel used in the VF gel
dosing phase does not have activity in the explant challenge model [12]. These data therefore
give significant encouragement to the possibility that RM could be used in a pericoital fashion.
PK/PD modeling has been used to characterize the relationship between systemic and local
drug concentrations and the ability to inhibit ex vivo viral replication in colorectal tissue
[28,31]. PK/PD modeling can also be used to help define therapeutic/pharmacokinetic targets
for microbicide development [28]. PK/PD data from the CHARM-01 study demonstrated a
significant negative correlation between increasing concentrations of TFV and decreasing lev-
els of ex vivo viral replication in colorectal tissue. Strikingly, the relationship was significant for
all PK matrices studied (plasma, rectal tissue (TFV and TFV-DP), rectal tissue-derived MMC
(TFV-DP), rectal fluid (TFV)).
The primary goal of the CHARM-01 study was to compare three different formulations of
TFV gel and to determine whether there were significant differences in safety, acceptability, PK,
or PD parameters that might facilitate deciding which product should be advanced into late
stage development as a RM. Given the unacceptable rectal safety profile of the VF TFV gel, docu-
mented in the RMP-02/MTN-006 study, it is clear that this is not a viable product to develop
further as a RM The real decision is whether CHARM-01 allows us to choose between the RF
and RGVF formulations of TFV gel. The CHARM-01 PK data do suggest that the RF formula-
tion may deliver higher local concentrations of TFV-DP to the rectal mucosa than the RGVF
formulation, although this did not reach significance. This is the only discriminating parameter
between the RF and RGVF TFV gels in the CHARM-01 study and may be insufficient to dis-
place the RGVF TFV gel that is currently being evaluated in theMTN-017 study, an Internation-
al Phase 2 expanded safety study being conducted in the United States, Peru, Thailand, and
South Africa. The results of the MTN-017 study (expected in early 2016), with approximately
192 participants, eight week periods of exposure to daily or pericoital RGVF TFV gel, as well as a
PK/PD substudy of 36 participants, will have a critical role in defining the future for the RGVF
TFV gel as a candidate RM for Phase 3 safety and effectiveness trials. Certainly, with increasing
rates of HIV infection in MSM and transgender women [2, 32] there is an urgent need to devel-
op new approaches for the prevention of HIV infection in these highly vulnerable populations.
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